Jones Pharma
 | This article has multiple issues. Please help improve it or discuss these issues on the talk page. (Learn how and when to remove these messages)
|
Jones Pharma is a specialty pharmaceuticals manufacturer and marketer based in St. Louis, Missouri. The company was founded on March 16, 1981, by Dennis M. Jones and Judith Pearce Jones under the name Jones Medical Industries. The company completed its initial public offering in 1986, trading under the ticker symbol JMED on the NASDAQ. The primary therapeutic compounds marketed by the company include Thrombin-JMI[1] and Levoxyl.[2] On May 30, 2000, the company became a wholly owned subsidiary of King Pharmaceuticals (NYSE:KG), based in Bristol, Tennessee. The market value of the company on its closing trade was $3.6 billion.[3][4] Parent company King Pharmaceuticals was acquired by Pfizer in 2010.[5][6]
References
[edit]- ^ "Thrombin-Jmi". thrombin-jmi.com. Retrieved 2014-12-14.
- ^ "Levoxyl® (levothyroxine sodium tablets, USP) | Safety Info". levoxyl.com. Retrieved 2014-12-14.
- ^ prnewswire.com Archived 2011-04-03 at the Wayback Machine
- ^ "Dennis Jones - St. Louis Business Journal". bizjournals.com. Retrieved 2014-12-14.
- ^ "Pfizer to buy King Pharma for $3.6 billion in cash". Reuters. 2010-10-12. Retrieved 2020-08-06.
- ^ Rockoff, Jonathan D. (2010-10-13). "Pfizer to Buy King Pharmaceuticals". Wall Street Journal. ISSN 0099-9660. Retrieved 2020-08-06.
- Socha, Rudy & Darrow, Carolyn (2003). "Above and Beyond: Former Marines Conquer the Civilian World", p. 110. Turner Publishing, Paducha. ISBN 1-56311-949-8
- Wall Street Journal Article Ranks Jones Pharma 23rd in Five-Year Return Among Top 1000 U.S. Companies Wall Street Journal Article Ranks Jones Pharma 23rd in Five-Year Return Among Top 1000 U.S. Companies
- King Pharmaceuticals merging with Jones Pharma in $3.4 Billion Deal thepharmaletter.com
- St. Louis Business Journal: He's a multimillionaire who never went to college, yet within 20 years built Jones Pharma into a business that was acquired for $3.4 billion [1]
- Read more: Dennis Jones - St. Louis Business Journal